Gilead Sciences Inc
NASDAQ: GILD
$91.87
+$0.87 (+1.0%)
Real Time Data Delayed 15 Min.
GILD Articles
ThinkstockGilead Sciences Inc. (NASDAQ: GILD) has been on fire, so much that two insiders decided to stuff their holiday stockings with about $23 million in stock sales. Chairman and CEO John Martin...
Published:
ThinkstockThe DJIA has finally closed above 16,000 for the first time ever. With a light holiday week coming up and with year-end just around the corner, investors have to consider research ideas...
Published:
ThinkstockAny time investors look for companies growing sales the most, one area that almost always stands out is the up and coming biotech stocks. After all, sales can grow from close to nothing...
Published:
ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies locally, but a new report from IMS Health shows that...
Published:
The Alpha Preference list of stocks to buy at UBS is comprised of companies that are the most preferred stocks to buy within the 41 major sectors that the firm covers. These are stocks that they...
Published:
Last Updated:
ThinkstockIdenix Pharmaceuticals Inc. (NASDAQ: IDIX) was the biggest gainer of all listed stocks on Friday with a rally of 40%. Its trading volume of almost 9.2 million shares was almost eight-times...
Published:
Jon OggWe are nearing the end of earnings season, and stocks have challenged new all-time highs. Now investors are starting to think about 2014, and the notion of which stocks to buy and which ones...
Published:
ThinkstockThe world of biotechnology investing is a constantly evolving and changing one. While disease for the most part does not change all that much, the manner in which it can be treated does....
Published:
ThinkstockThe field of pharmaceuticals is very well established and often is considered to be a very defensive sector. As such, investors flock to the drug sector in times of uncertainty. But what...
Published:
ThinkstockTuesday saw the wrap up of the 2013 European Society of Medical Oncology (ESMO) conference in Amsterdam, which featured key data from several of the companies covered by the biotech...
Published:
Last Updated:
ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in their...
Published:
Last Updated:
ThinkstockAlpha is one of those confusing terms that is used in the financial industry but rarely defined. It is basically a performance measurement on a risk-adjusted basis. Alpha takes the...
Published:
When we screen stocks at the Wall Street firms we cover, we always are anxious to provide our readers with the stocks that the top firms feel have the most upside from current trading levels to their...
Published:
Last Updated:
ThinkstockThe higher the market climbs, the harder it becomes for investors to find solid stock ideas to add or scale in to their portfolios. With the market currently teetering on what seems like an...
Published:
Last Updated:
ThinkstockBiotech has strongly outperformed the S&P 500 since January of 2011. The NASDAQ Biotechnology Index (NBI) is up 90%, and the AMEX Biotechnology index (BTK) is up 50%, versus the 28%...
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.